RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates

RxSight, which belongs to the Zacks Medical - Instruments industry, posted revenues of $33.64 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.11%. This compares to year-ago revenues of $34.89 million. The company has topped consensus revenue estimates four times over the last four quarters. RxSight, Inc. (RXST) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to break-even earnings per share a year ag ...